Drug intelligence / Profile preview

bromhexine + guaifenesin + menthol + terbutaline

Development stage
Unknown
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination pharmaceutical used for the **treatment of cough and respiratory disorders** associated with excessive or thick mucus, such as bronchitis, bronchial asthma, emphysema, and chronic obstructive pulmonary disease. - **Bromhexine** is a mucolytic agent that thins and loosens mucus in the airways, making it easier to expel. - **Guaifenesin** acts as an expectorant by increasing the hydration of secretions and decreasing their viscosity, aiding in the clearance of mucus. - **Menthol** provides a sensation of coolness and relieves minor throat irritation by its local soothing effects. - **Terbutaline** is a bronchodilator that relaxes airway smooth muscle via beta-2 adrenergic receptor agonism, making breathing easier and helping to relieve bronchospasm. It is most often formulated as a **syrup for oral administration** and is indicated for productive cough where bronchospasm and mucus plugging co-exist[1][2][5][3].

Brand names
Brox-TR
Other names
bromhexine + guaifenesin + menthol + terbutaline
02

Targets

ADRB2 (β2)MUC5B (Mucin-5B)MUC2 (Mucin-2)

Beyond the preview

Go deeper on bromhexine + guaifenesin + menthol + terbutaline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bromhexine + guaifenesin + menthol + terbutaline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call